


February 20, 2025
J-Pharma Co., Ltd.

Announcement of presentation at the J.P. Morgan, UC Berkeley Healthcare Conference Taipei 2025

J-Pharma Co., Ltd. (Headquarters: Yokohama, Kanagawa Prefecture, President & CEO: Masuhiro Yoshitake) is pleased to announce that Mr. Yutaka Fujimoto, Director and Chief Financial Officer (CFO) of J-Pharma, made a presentation at the J.P. Morgan, UC Berkeley Healthcare Conference Taipei 2025 held from February 19 to February 20, 2025.



Mr. Fujimoto's presentation concentrated on J-Pharma's plans to initiate a global Phase 3 study of our lead compound, *nanvuranlat*, for the second-line treatment of biliary tract cancer in 2025. J-Pharma also plans to initiate three other clinical trials in 2025 to demonstrate the transformative potential of LAT1 inhibitors. In this presentation, we discussed the aims and progress of these clinical programs.

1. Date and Time: Wednesday February 19, 2025, 14:00 – 14: 15 (local Time)
2. Venue: The Regent Hotel Taipei, Taiwan
3. Presenter: Mr. Yutaka Fujimoto, Director & CFO

Inquiries:
J-Pharma Co., Ltd.
Administration Department
Public Relations
<https://www.j-pharma.com/en/contact>